| Prev Close | 3.36 |
| Open | 3.36 |
| Day Low/High | 3.36 / 3.46 |
| 52 Wk Low/High | 2.53 / 3.96 |
| Volume | 619.47K |
| Avg Volume | 836.00K |
Antares Pharma Appoints David H. Bergstrom Ph.D. As Senior Vice President Pharmaceutical Development
Antares Pharma, Inc. (NASDAQ:ATRS) today announced the appointment of David H.
Antares Pharma To Present At The Jefferies 2013 Global Healthcare Conference
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.
Antares Pharma Enters Into An Exclusive U.S. Promotion And Marketing Agreement With LEO Pharma For OTREXUP™ In Dermatology
Antares Pharma, Inc. (NASDAQ: ATRS) today announced an exclusive promotion and marketing agreement with LEO Pharma for detailing OTREXUP ™ (methotrexate) to dermatologists for symptomatic control of severe ...
Antares Pharma Reports Third Quarter 2013 Operating And Financial Results
Antares Pharma, Inc. (NASDAQ:ATRS) today reported operating and financial results for the third quarter ended September 30, 2013.
Antares Pharma Appoints Dr. Bruce Freundlich As Senior Vice President
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Dr.
Antares Pharma To Host Third Quarter 2013 Operating And Financial Results Conference Call
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its third quarter 2013 financial results before the market opens on Wednesday, November 6, 2013, and host a conference call shortly thereafter at 8:30...
Antares Pharma Announces The Issuance Of A New U.S. Patent On The VIBEX® Device Platform
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.
First Week Of ATRS December 21st Options Trading
Investors in Antares Pharma Inc. saw new options begin trading this week, for the December 21st expiration.
Antares Announces Podium Presentation Of Pivotal OTREXUP™ (methotrexate) Data At American College Of Rheumatology Annual Meeting
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that data from a pivotal clinical trial of OTREXUP™ (methotrexate) for subcutaneous injection were selected for live, oral presentation during a clinical ...
Antares' Otrexup Approval Was Easy, Selling Drug Will be Hard
Doctors are unlikely to embrace Otrexup for rheumatoid arthritis patients without more efficacy data.
OTREXUP™ (methotrexate) Injection Approved By FDA A New Treatment For Adults With Rheumatoid Arthritis, Children With Polyarticular Idiopathic Arthritis, And Adults With Psoriasis
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the approval of OTREXUP ™ (methotrexate) injection by the U.
4 Biotech Stocks Under $10 Making Moves
Keep these biotech stocks on your radar.
First Week Of May 2014 Options Trading For Antares Pharma (ATRS)
Investors in Antares Pharma Inc. saw new options begin trading this week, for the May 2014 expiration.
Antares Pharma Announces First Patients Dosed In VIBEX™ QS T Study Evaluating Testosterone Deficient Males
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the first patients have been dosed in a clinical study evaluating testosterone enanthate administered weekly by subcutaneous injection at doses of 50 mg and 100...
Ratings Changes Today
Upgrades: ATRS, BREW, OFG Downgrades: BBGI, MS, NRP, PERY, UEPS Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
3 Stocks Under $10 Moving Higher
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Antares Pharma Reports Second Quarter 2013 Operating And Financial Results
Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the second quarter ended June 30, 2013.
Antares Pharma To Host Second Quarter 2013 Operating And Financial Results Conference Call
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its second quarter 2013 financial results before the market opens on Wednesday, August 7, 2013, and host a conference call shortly thereafter at 8:30...
Antares Pharma Welcomes Robert P. Roche Jr. To Board Of Directors
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the election of Robert P.
First Week Of ATRS September 21st Options Trading
Investors in Antares Pharma Inc. saw new options become available this week, for the September 21st expiration.
Biotech Stock Mailbag: Antares Pharma, NewLink, Celgene
Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.
Antares Pharma Announces The Issuance Of A New U. S. Patent For OTREXUP™
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has received a Notice of Issuance from the U.
Subcutaneous, Self-Administered Methotrexate For Rheumatoid Arthritis Demonstrated Significantly Greater Bioavailability Over Current Standard Of Care
Antares Pharma, Inc. (NASDAQ: ATRS) today announced subcutaneous methotrexate delivered with a new, self-administration device demonstrates bioavailability that is significantly greater than oral methotrexate in the...
2013 FDA Drug Approval Calendar
An updated list of the biotech and drug firms expecting FDA drug approval decisions in 2013.
5 Stocks Under $10 Set to Soar
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
Antares Pharma Reports Fourth Quarter And Full Year 2012 Operating And Financial Results
Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the fourth quarter and full year ended December 31, 2012.
Antares Pharma To Host Fourth Quarter 2012 Call
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its fourth quarter 2012 financial results before the market opens on Wednesday, March 13, 2013, and host a conference call shortly thereafter at 8:30...
Antares Pharma Announces FDA Acceptance Of New Drug Application For OTREXUP™
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the New Drug Application (NDA) for OTREXUP™, a potential new product for the subcutaneous delivery of methotrexate (MTX) using Medi-Jet™ technology, ...
Antares Pharma To Present At The Cowen And Company 33rd Annual Healthcare Conference
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.
Antares Pharma To Participate In The 2013 RBC Capital Markets’ Healthcare Conference
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.
